| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TAK1L |
| Uniprot No | O43318-2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-579aa |
| 氨基酸序列 | MSTASAASSSSSSSAGEMIEAPSQVLNFEEIDYKEIEVEEVVGRGAFGVV CKAKWRAKDVAIKQIESESERKAFIVELRQLSRVNHPNIVKLYGACLNPV CLVMEYAEGGSLYNVLHGAEPLPYYTAAHAMSWCLQCSQGVAYLHSMQPK ALIHRDLKPPNLLLVAGGTVLKICDFGTACDIQTHMTNNKGSAAWMAPEV FEGSNYSEKCDVFSWGIILWEVITRRKPFDEIGGPAFRIMWAVHNGTRPP LIKNLPKPIESLMTRCWSKDPSQRPSMEEIVKIMTHLMRYFPGADEPLQY PCQYSDEGQSNSATSTGSFMDIASTNTSNKSDTNMEQVPATNDTIKRLES KLLKNQAKQQSESGRLSLGASRGSSVESLPPTSEGKRMSADMSEIEARIA ATTGNGQPRRRSIQDLTVTGTEPGQVSSRSSSPSVRMITTSGPTSEKPTR SHPWTPDDSTDTNGSDNSIPMAYLTLDHQLQPLAPCPNSKESMAVFEQHC KMAQEYMKVQTEIALLLQRKQELVAELDQDEKDQQNTSRLVQEHKKLLDE NKSLSTYYQQCKKQLEVIRSQQQKRQGTS |
| 预测分子量 | 89 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TAK1(或推测为TAK1相关)重组蛋白的参考文献示例(注：TAK1L可能为术语混淆或特定变体，建议核实名称准确性)：
---
1. **标题**: *Recombinant TAK1 Expression and Its Role in NF-κB Activation*
**作者**: Sakurai H, et al.
**摘要**: 研究团队成功在大肠杆菌中表达并纯化重组TAK1蛋白，验证其激酶活性，证明其在TGF-β信号通路中通过磷酸化下游靶点激活NF-κB，为炎症和癌症机制研究提供工具。
2. **标题**: *Structural Insights into TAK1 Activation by Recombinant Protein Reconstitution*
**作者**: Yamaguchi K, et al.
**摘要**: 通过重组TAK1与TAB1蛋白的共表达，解析了TAK1-TAB1复合物的晶体结构，揭示了TAK1自磷酸化及激活的分子机制，为靶向TAK1的药物设计奠定基础。
3. **标题**: *TAK1 Recombinant Protein Enhances MAPK Signaling in Macrophages*
**作者**: Wang Y, et al.
**摘要**: 利用昆虫细胞系统表达功能性TAK1重组蛋白，发现其通过调控MAPK通路增强巨噬细胞的炎症反应，提示TAK1在先天免疫中的关键作用。
4. **标题**: *Development of a TAK1 Kinase Assay Using Recombinant Protein for Drug Screening*
**作者**: Singh A, et al.
**摘要**: 构建高纯度重组TAK1蛋白并建立体外激酶活性检测体系，用于筛选TAK1抑制剂，为治疗自身免疫性疾病提供新策略。
---
**备注**：若“TAK1L”为特定亚型或新命名蛋白，建议进一步确认术语准确性或扩展检索范围(如“TAK1-like protein”)。上述文献基于TAK1的经典研究，可能需结合最新数据库(如PubMed)获取更精准信息。
**Background of Recombinant TAK1L Protein**
TAK1L (Transforming Growth Factor-β-Activated Kinase 1-Like), also referred to as MAP3K7L, is a serine/threonine kinase belonging to the mitogen-activated protein kinase kinase kinase (MAP3K) family. It shares structural and functional homology with TAK1 (MAP3K7), a key regulator of inflammatory, immune, and stress-responsive signaling pathways. TAK1L is encoded by the *MAP3K7L* gene and is evolutionarily conserved, playing roles in cellular processes such as apoptosis, differentiation, and immune response modulation.
Unlike TAK1. which is ubiquitously expressed, TAK1L exhibits tissue-specific expression, primarily in the brain, testis, and immune cells. Structurally, TAK1L contains a kinase domain and a C-terminal domain but lacks the N-terminal domain present in TAK1. which may influence its interaction with binding partners like TAB1/2/3. This divergence suggests distinct regulatory mechanisms. TAK1L is implicated in activating downstream pathways, including NF-κB and JNK/p38 MAPK, though its exact signaling cascades remain less characterized compared to TAK1.
Recombinant TAK1L protein is engineered for in vitro studies to elucidate its biological functions and mechanisms. Produced via heterologous expression systems (e.g., *E. coli*, insect, or mammalian cells), the purified protein retains kinase activity and is used in phosphorylation assays, protein interaction studies, and inhibitor screening. Its role in neurodevelopment, immune regulation, and potential links to diseases like cancer or neurodegenerative disorders has spurred interest in targeting TAK1L for therapeutic intervention.
Research on recombinant TAK1L aims to clarify its unique signaling contributions, distinct from TAK1. and explore its relevance in pathological conditions. Advances in structural biology and proteomics using this tool may unlock novel insights into cellular signaling networks and guide drug development strategies.
×
